J.j. (jaap-jan) Boelens

Biography

Jaap-Jan Boelens is a pediatrician – oncologist/Immunologist. He received his PhD at the University of Amsterdam/Academic Medical Center in 1999. He was trained as a paediatrician in the Leiden UMC and the Juliana Children’s Hospital in Den Haag followed by completion of clinical fellowship in immunology (2006, UMC Utrecht) and oncology (2011, ErasmusMC, Rotterdam). His clinical sub-specialization is Hemapoietic Cell Transplantation (HCT) and he is working as a consultant in HCT at the UMC Utrecht since 2006. He has a special interest in rare-diseases (as indication for HCT) in particular “lysosomal storage diseases” and finding strategies to get better disease control (in malignant diseases). His research group (Group Boelens / Nierkens: U-DANCE) focuses on the development of cord blood derived dendritic cell vaccines (anti-AML, anti-Neuroblastoma). In addition there is a special interest designing a predictable low toxic conditioning regimen using PK/PD-models for e.g. ATG (anti-thymocyte globuline) to better predict the immune-reconstitution (nessasary for optimal effect vaccines). In his group are 4 PostDocs, 5 PhD students and 3 technicians working. He is a frequently invited speaker on international conferences and has over 130 peer-reviewed publications. He is (co-)PI on various phase I/II trials with ATMPs. He is VP elect of the ISCT EU (2016-2018) and will the VP of ISCT EU from 2018-2020 and is also director of the CBA (Cord Blood Association) board (till 2020). Jaap-Jan Boelens is a pediatrician – oncologist/Immunologist. He received his PhD at the University of Amsterdam/Academic Medical Center in 1999. He was trained as a paediatrician in the Leiden UMC and the Juliana Children’s Hospital in Den Haag followed by completion of clinical fellowship in immunology (2006, UMC Utrecht) and oncology (2011, ErasmusMC, Rotterdam). His clinical sub-specialization is Hemapoietic Cell Transplantation (HCT) and he is working as a consultant in HCT at the UMC Utrecht since 2006. He has a special interest in rare-diseases (as indication for HCT) in particular “lysosomal storage diseases” and finding strategies to get better disease control (in malignant diseases). His research group (Group Boelens / Nierkens: U-DANCE) focuses on the development of cord blood derived dendritic cell vaccines (anti-AML, anti-Neuroblastoma). In addition there is a special interest designing a predictable low toxic conditioning regimen using PK/PD-models for e.g. ATG (anti-thymocyte globuline) to better predict the immune-reconstitution (nessasary for optimal effect vaccines). In his group are 4 PostDocs, 5 PhD students and 3 technicians working. He is a frequently invited speaker on international conferences and has over 130 peer-reviewed publications. He is (co-)PI on various phase I/II trials with ATMPs. He is VP elect of the ISCT EU (2016-2018) and will the VP of ISCT EU from 2018-2020 and is also director of the CBA (Cord Blood Association) board (till 2020).

Research Interest

Oncology/Immunology